Pulmonx: 3 Key Takeaways for Long-Term Investors
On its third-quarter 2026 earnings call, held on Oct. 27, 2026, Pulmonx (NASDAQ:LUNG) returned to year-over-year top-line growth with total revenue of $22.8 million. Commercial realignments and expense controls are narrowing losses while expanding the reach of its medical devices for severe lung disease. Three management statements highlight the drivers behind this financial turn. Pulmonx reduced its third-quarter adjusted EBITDA loss, or earnings before interest, taxes, depreciation, and amortization, by nearly 60% year over year. Lower operating expenses provided immediate financial leverage as revenue expanded. Continue reading